Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/34157
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBorimas Hanboonkunupakarnen_US
dc.contributor.authorElizabeth A. Ashleyen_US
dc.contributor.authorPodjanee Jittamalaen_US
dc.contributor.authorJoel Tarningen_US
dc.contributor.authorSasithon Pukrittayakameeen_US
dc.contributor.authorWarunee Hanpithakpongen_US
dc.contributor.authorPalang Chotsirien_US
dc.contributor.authorThanaporn Wattanakulen_US
dc.contributor.authorSalwaluk Panapipaten_US
dc.contributor.authorSue J. Leeen_US
dc.contributor.authorNicholas P.J. Dayen_US
dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherNuffield Department of Clinical Medicineen_US
dc.date.accessioned2018-11-09T02:32:02Z-
dc.date.available2018-11-09T02:32:02Z-
dc.date.issued2014-12-01en_US
dc.identifier.citationAntimicrobial Agents and Chemotherapy. Vol.58, No.12 (2014), 7340-7346en_US
dc.identifier.issn10986596en_US
dc.identifier.issn00664804en_US
dc.identifier.other2-s2.0-84913593970en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84913593970&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/34157-
dc.description.abstract© 2014 Hanboonkunupakarn et al. Dihydroartemisinin-piperaquine is an artemisinin-based combination treatment (ACT) recommended by theWHOfor uncomplicated Plasmodium falciparum malaria, and it is being used increasingly for resistant vivax malaria where combination with primaquine is required for radical cure. TheWHOrecently reinforced its recommendations to add a single dose of primaquine to ACTs to reduce P. falciparum transmission in low-transmission settings. The pharmacokinetics of primaquine and dihydro-artemisinin- piperaquine were evaluated in 16 healthy Thai adult volunteers in a randomized crossover study. Volunteers were randomized to two groups of three sequential hospital admissions to receive 30 mg (base) primaquine, 3 tablets of dihydroarte-misinin- piperaquine (120/960 mg), and the drugs together at the same doses. Blood sampling was performed over 3 days following primaquine and 36 days following dihydroartemisinin-piperaquine dosing. Pharmacokinetic assessment was done with a noncompartmental approach. The drugs were well tolerated. There were no statistically significant differences in dihydroartemisinin and piperaquine pharmacokinetics with or without primaquine. Dihydroartemisinin-piperaquine coadministration significantly increased plasma primaquine levels; geometric mean ratios (90% confidence interval [CI]) of primaquine combined versus primaquine alone for maximum concentration (Cmax), area under the concentration-time curve from 0 h to the end of the study (AUC0-last), and area under the concentration-time curve from 0 h to infinity (AUC0-∞) were 148% (117 to 187%), 129% (103 to 163%), and 128% (102 to 161%), respectively. This interaction is similar to that described recently with chloroquine and may result in an enhanced radical curative effect. (This study has been registered at ClinicalTrials.gov under registration no. NCT01525511.)en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84913593970&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleOpen-label crossover study of primaquine and dihydroartemisinin- Piperaquine pharmacokinetics in healthy adult thai subjectsen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.1128/AAC.03704-14en_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.